

Accepted Manuscript

Efficacy of clarithromycin-naproxen-oseltamivir combination in the treatment of patients hospitalized for influenza A(H3N2) infection: an open-label, randomized controlled, phase 2b/3 trial

Ivan FN. Hung, MD, Kelvin KW. To, MD, Jasper FW. Chan, MBBS, Vincent CC. Cheng, MD, Kevin SH. Liu, MBChB, Anthony Tam, MBBS, Tuen-Ching Chan, MD, Anna Jinxia Zhang, PhD, Patrick Li, MSc, Tin-Lun Wong, BSc, Ricky Zhang, MSc, Michael KS. Cheung, William Leung, MBBS, Johnson YN. Lau, MD, Manson Fok, MD, Honglin Chen, PhD, Kwok-Hung Chan, PhD, Kwok-Yung Yuen, MD

PII: S0012-3692(16)62393-0

DOI: [10.1016/j.chest.2016.11.012](https://doi.org/10.1016/j.chest.2016.11.012)

Reference: CHEST 818

To appear in: *CHEST*


Received Date: 1 August 2016

Revised Date: 6 November 2016

Accepted Date: 8 November 2016

Please cite this article as: Hung IF, To KK, Chan JF, Cheng VC, Liu KS, Tam A, Chan TC, Zhang AJ, Li P, Wong TL, Zhang R, Cheung MK, Leung W, Lau JY, Fok M, Chen H, Chan KH, Yuen KY, Efficacy of clarithromycin-naproxen-oseltamivir combination in the treatment of patients hospitalized for influenza A(H3N2) infection: an open-label, randomized controlled, phase 2b/3 trial, *CHEST* (2016), doi: 10.1016/j.chest.2016.11.012.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Efficacy of clarithromycin-naproxen-oseltamivir combination in the treatment of patients hospitalized for influenza A(H3N2) infection: an open-label, randomized controlled, phase 2b/3 trial

Ivan FN Hung MD^{1,2}, Kelvin KW To MD¹, Jasper FW Chan MBBS¹, Vincent CC Cheng MD¹, Kevin SH Liu MBChB², Anthony Tam MBBS², Tuen-Ching Chan MD², Anna Jinxia Zhang PhD¹, Patrick Li MSc¹, Tin-Lun Wong BSc¹, Ricky Zhang MSc², Michael KS Cheung², William Leung MBBS³, Johnson YN Lau MD¹, Manson Fok MD¹, Honglin Chen PhD^{1,4}, Kwok-Hung Chan PhD¹, Kwok-Yung Yuen MD^{1,4}.

Carol Yu Centre for Infection and Division of Infectious Diseases, State Key Laboratory of Emerging Infectious Diseases, Department of Microbiology, the University of Hong Kong, Queen Mary Hospital, Hong Kong Special Administrative Region, China¹

Department of Medicine, the University of Hong Kong, Queen Mary Hospital, Hong Kong Special Administrative Region, China²

LKS Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China³

Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Zhejiang University, Hangzhou, China⁴

Correspondence to:

Kwok-Yung Yuen, Carol Yu Centre for Infection and Division of Infectious Diseases, Department of Microbiology, The University of Hong Kong, Queen Mary Hospital, 102 Pokfulam Road, Pokfulam, Hong Kong Special Administrative Region, China.

(E-mail: kyyuen@hku.hk)

Conflicts of Interest: JFW Chan has received travel grants from Pfizer Corporation

Download English Version:

<https://daneshyari.com/en/article/5600928>

Download Persian Version:

<https://daneshyari.com/article/5600928>

[Daneshyari.com](https://daneshyari.com)